Osteoporosis Diagnosis, Risk Assessment, and Management Guidelines

Diagnosis & Screening

All postmenopausal women ≥ 65 years, men > 70 years, and adults ≥ 50 years with risk factors should receive DXA BMD testing of the lumbar spine, total hip, femoral neck, and, when indicated, the one‑third radius. Strong recommendation. 1
Osteoporosis is diagnosed when the lowest T‑score at any measured site (lumbar spine, femoral neck, total hip, or one‑third radius) is ≤ ‑2.5. Strong recommendation. 1
Presence of a low‑trauma major fracture (hip, spine, forearm, humerus, pelvis) establishes the diagnosis of osteoporosis regardless of BMD. Strong recommendation. 1
T‑scores must be calculated using the NHANES III reference database derived from healthy White women aged 20–29 years. Strong recommendation. 1
Vertebral fracture assessment (VFA) by DXA or conventional radiography is indicated in patients ≥ 50 years with T‑score < ‑1.0, height loss > 4 cm, self‑reported vertebral fracture, or chronic glucocorticoid use. Strong recommendation. 1

Clinical Risk Factors

Key risk factors to assess include advanced age, current smoking, excessive alcohol (≥ 3 drinks/day), prior fragility fracture, parental hip fracture, low body weight, glucocorticoid therapy, hypogonadism, reduced mobility, increased fall risk, and postmenopausal status. Strong recommendation. 2, 3

Fracture Risk Assessment Tools

The FRAX tool should be applied in adults ≥ 40 years to estimate 10‑year probability of major osteoporotic and hip fractures. Strong recommendation. 2, 4
FRAX is not validated for individuals < 40 years or for serial reassessment during osteoporosis therapy. Conditional recommendation. 5
Treatment thresholds: 10‑year major osteoporotic fracture probability ≥ 20 % or hip fracture probability ≥ 3 % warrant pharmacologic therapy. Strong recommendation. 4
FRAX does not incorporate falls, fracture timing, or frailty; clinical judgment must supplement FRAX estimates. Conditional recommendation. 5

Non‑Pharmacologic Management

Calcium intake of 1,000–1,200 mg/day (dietary plus supplements if needed). Strong recommendation. 2, 4
Vitamin D supplementation of at least 800–1,000 IU/day. Strong recommendation. 2, 4
Regular exercise combining balance training, flexibility/stretching, endurance, and progressive resistance strengthening. Strong recommendation. 4
Smoking cessation and limiting alcohol to ≤ 1–2 drinks/day. Strong recommendation. 6, 4
Weight‑bearing activity and maintenance of a healthy body weight. Strong recommendation. 5, 6

Pharmacologic Treatment – Risk Stratification

Very High Fracture Risk (3‑year risk ≥ 10 %)

Anabolic agents (teriparatide, abaloparatide, or romosozumab) are conditionally recommended as first‑line, preferred over anti‑resorptives. 5, 7

High Fracture Risk

Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are strongly recommended as first‑line therapy. 5, 7, 6
If oral bisphosphonates are unsuitable, denosumab 60 mg SC every 6 months or IV zoledronic acid 5 mg annually are conditionally recommended alternatives. 8, 4
For adults ≥ 40 years at high risk, denosumab or PTH/PTHrP agents are conditionally recommended over bisphosphonates. 5, 7

Moderate Fracture Risk (3‑year risk > 3 %)

Oral or IV bisphosphonates, denosumab, or PTH/PTHrP agents are conditionally recommended; choice should consider adherence potential, gastrointestinal tolerability, cost, and safety profile. 5, 7, 6, 8

Specific Pharmacologic Details

Oral bisphosphonates: alendronate 70 mg weekly, risedronate 35 mg weekly, ibandronate 150 mg monthly; GI adverse effects may limit adherence. Conditional recommendation. 8
IV bisphosphonate (zoledronic acid): 5 mg once yearly; may cause an acute‑phase reaction (fever, myalgias) treatable with acetaminophen or ibuprofen. Conditional recommendation. 8
Denosumab: 60 mg SC every 6 months; discontinuation without subsequent bisphosphonate therapy carries a high risk of rebound vertebral fractures, therefore a transition to a bisphosphonate is mandatory. Strong recommendation. 5, 7, 2
Denosumab safety: insufficient data in immunosuppressed patients. Conditional recommendation. 6
Anabolic agents: teriparatide or abaloparatide administered daily subcutaneously; romosozumab provides dual anabolic/anti‑resorptive action. After discontinuation, sequential therapy with a bisphosphonate is required to prevent bone loss. Conditional recommendation. 6, 8, 7, 5
Raloxifene: reserved for postmenopausal women when other agents are unsuitable; strong recommendation against using estrogen, estrogen + progestogen, or raloxifene as primary osteoporosis therapy in most women. Strong recommendation. 6, 3

Treatment Monitoring

Follow‑up DXA BMD testing should be performed 1–5 years after initiating or changing therapy, tailored to clinical circumstances. Strong recommendation. 1
Routine BMD monitoring during the first 5 years of pharmacologic treatment is not recommended. Strong recommendation. 3
Each imaging facility must determine its precision error and calculate the least significant change (LSC) for reliable interpretation. Strong recommendation. 1
Ideally, follow‑up DXA should be performed at the same center using the same scanner to ensure consistency. Strong recommendation. 1

Sequential Therapy Principle

After stopping denosumab, romosozumab, or PTH/PTHrP agents, a bisphosphonate must be initiated to prevent rebound bone loss and vertebral fractures. Strong recommendation. 5, 7, 2

Special Populations

Glucocorticoid‑Induced Osteoporosis (GIOP)

Adults receiving ≥ 2.5 mg/day prednisone (or equivalent) for > 3 months should be screened within 6 months using FRAX (age ≥ 40) plus DXA with VFA or spine radiographs. Strong recommendation. 5, 9, 10
For prednisone > 7.5 mg/day, apply the FRAX glucocorticoid dose‑adjustment factor. Conditional recommendation. 5
Patients with medium, high, or very high fracture risk should receive osteoporosis therapy; oral bisphosphonates are strongly recommended for high/very high risk. Strong recommendation. 5, 10, 7

Cancer Survivors (Aromatase Inhibitors, ADT, GnRH Agonists)

Offer bone‑modifying agents when T‑score ≤ ‑2.5 or FRAX 10‑year risk ≥ 20 % for major fractures or ≥ 3 % for hip fracture. Strong recommendation. 4
Therapeutic options include oral bisphosphonates, IV bisphosphonates, or denosumab at osteoporosis‑approved doses. Strong recommendation. 4
Perform BMD assessment every 2 years (more frequently if near treatment thresholds). Strong recommendation. 4

Adults < 40 Years

Low‑risk individuals should receive calcium, vitamin D, and lifestyle optimization without pharmacologic therapy. Strong recommendation. 6
Moderate‑to‑high‑risk individuals may be treated with oral bisphosphonates on a conditional basis. Conditional recommendation. 6
Use Z‑scores (not T‑scores); a Z‑score ≤ ‑2.0 indicates low bone mass for age. Strong recommendation. 5

Common Pitfalls

Failure to transition patients off denosumab, romosozumab, or PTH/PTHrP to a bisphosphonate markedly increases the risk of severe rebound vertebral fractures. Strong recommendation. 5, 2
FRAX underestimates fracture risk in patients on very high glucocorticoid doses (≥ 30 mg/day prednisone). Conditional recommendation. 5
Relying solely on BMD without incorporating clinical risk factors leads to missed high‑risk patients. Strong recommendation. 3
Using IV bisphosphonates in low‑risk patients < 40 years exposes them to unnecessary adverse effects. Conditional recommendation. 6
Prescribing denosumab to immunosuppressed patients without adequate safety data is discouraged. Conditional recommendation. 6

Indications for Proton Pump Inhibitor (PPI) Use in Patients Receiving Systemic Glucocorticoids

When PPIs May Be Considered

In adults on chronic glucocorticoid therapy, a PPI should only be prescribed if a high‑risk gastrointestinal indication is present—such as a documented complicated GI event, concurrent aspirin therapy, or age ≥ 65 years—because these factors justify the potential benefit of acid suppression despite the added fracture risk 11.

When PPIs Should Be Avoided

In the same glucocorticoid‑treated population, PPIs should be omitted when no high‑risk gastrointestinal indication exists, to prevent unnecessary amplification of osteoporosis‑related fracture risk 11.

Evidence‑Based Osteoporosis Diagnosis, Risk Assessment, and Management

Diagnostic Evaluation & Laboratory Assessment

When bone mineral density (BMD) is unexpectedly low or osteoporosis presents with atypical features (e.g., young age, abnormal alkaline phosphatase), clinicians should evaluate secondary causes and consider referral to an endocrinology specialist. – American College of Endocrinology & American Association of Clinical Endocrinologists 12
Serum 25‑hydroxyvitamin D should be measured in patients at risk for deficiency; a target level of ≥30 ng/mL is recommended to prevent secondary hyperparathyroidism. – American College of Endocrinology & American Association of Clinical Endocrinologists 13
Calcium and vitamin D deficiencies must be corrected before initiating osteoporosis pharmacotherapy. – American College of Endocrinology & American Association of Clinical Endocrinologists 12

Fracture‑Risk Assessment & Treatment Thresholds

Apply the FRAX tool in adults ≥40 years to estimate 10‑year major osteoporotic and hip fracture probabilities; pharmacologic therapy is indicated when the 10‑year major osteoporotic fracture risk is ≥20 % or the hip fracture risk is ≥3 %. – American College of Endocrinology & American Association of Clinical Endocrinologists; American Family Physician 12, 14
Very high fracture risk (3‑year risk ≥10 %) is defined by any of the following: advanced age, frailty, glucocorticoid use, very low BMD (T‑score ≤ ‑3.0), prior fragility fracture, or high fall risk. – American College of Endocrinology & American Association of Clinical Endocrinologists 12
High fracture risk is met by a T‑score ≤ ‑2.5, a history of fragility fracture, or FRAX estimates that meet the treatment thresholds above. – American College of Endocriology & American Association of Clinical Endocrinologists 12

Non‑Pharmacologic Management

All patients should receive 1,000–1,200 mg/day elemental calcium (dietary plus supplements) and 800–1,000 IU/day vitamin D. – American Family Physician; American College of Endocrinology & American Association of Clinical Endocrinologists 14, 13
Fall‑prevention programs and targeted physical‑therapy (balance, strength, and flexibility training) are recommended to reduce fracture risk. – American College of Endocrinology & American Association of Clinical Endocrinologists 13

Pharmacologic Therapy

Very High Fracture Risk (≥10 % 3‑year risk)

Anabolic agents (teriparatide, abaloparatide, or romosozumab) are the preferred first‑line options over anti‑resorptives. – American College of Endocrinology & American Association of Clinical Endocrinologists 15
Romosozumab provides combined anabolic and anti‑resorptive effects. – American College of Endocrinology & American Association of Clinical Endocrinologists 15

High Fracture Risk

Oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly, or ibandronate 150 mg monthly) are first‑line; they must be taken on an empty stomach with a full glass of water, and the patient should remain upright for at least 30 minutes. – American Family Physician 14
If oral bisphosphonates are contraindicated or not tolerated, denosumab 60 mg subcutaneously every 6 months or intravenous zoledronic acid 5 mg annually are acceptable alternatives. – American Family Physician; Arthritis & Rheumatology (American College of Rheumatology) 14, 16

Drug Holiday Considerations

A drug holiday may be considered after 5 years of oral bisphosphonate therapy or after 3 years of intravenous bisphosphonate therapy (6 years for zoledronic acid). – American College of Endocrinology & American Association of Clinical Endocrinologists 12
During a holiday, clinicians should reassess adherence, evaluate for secondary osteoporosis, and may use a weaker anti‑resorptive (e.g., raloxifene) or an anabolic agent if needed. – American College of Endocriology & American Association of Clinical Endocrinologists 12
Therapy should be resumed if a fracture occurs, BMD declines beyond the least‑significant change, bone‑turnover markers rise to pretreatment levels, or the patient again meets initial treatment criteria. – American College of Endocriology & American Association of Clinical Endocrinologists 12

Monitoring & Follow‑Up

Repeat DXA BMD testing is recommended 1–5 years after initiating or changing therapy, with yearly clinical reassessment for treatment response. – American College of Endocrinology & American Association of Clinical Endocrinologists 12
Bone‑turnover markers (BTMs) can be used to gauge fracture risk and early drug efficacy, and to assess adherence, but they are not required for all patients. – American College of Endocriology & American Association of Clinical Endocrinologists 13

Glucocorticoid‑Induced Osteoporosis (GIOP)

Adults on ≥2.5 mg/day prednisone (or equivalent) for >3 months should be screened within 6 months using FRAX (age ≥40) plus DXA with vertebral‑fracture assessment or spine radiographs. – American College of Rheumatology 16
For prednisone doses >7.5 mg/day, apply the FRAX glucocorticoid dose‑adjustment factor. – American College of Rheumatology 16
High or very high‑risk GIOP patients should receive oral bisphosphonates as first‑line therapy; the treatment hierarchy is oral bisphosphonates → IV bisphosphonates → teriparatide → denosumab (limited safety data in immunosuppressed patients). – American College of Rheumatology 16

Special Populations

Women of child‑bearing potential who are not planning pregnancy may be considered for oral bisphosphonate therapy on a conditional basis. – American College of Rheumatology 16

Treatment Failure & Therapy Switching

If bone loss progresses or fractures recur while on oral therapy, switch to an injectable anti‑resorptive (e.g., denosumab). – American College of Endocrinology & American Association of Clinical Endocrinologists 12
If a patient is already on an injectable anti‑resorptive and experiences failure, switch to an anabolic agent (abaloparatide, romosozumab, or teriparatide). – American College of Endocrinology & American Association of Clinical Endocrinologists 12
Continue therapy until the patient is no longer classified as high risk, ensuring a seamless transition to another anti‑resorptive to maintain bone protection. – American College of Endocrinology & American Association of Clinical Endocrinologists 12

Patient Education & Shared Decision‑Making

Providing education on lifestyle measures, fall prevention, and clear communication of medication benefits/risks improves adherence and clinical outcomes. – American College of Endocrinology & American Association of Clinical Endocrinologists; American College of Endocrinology & American Association of Clinical Endocrinologists 12, 15
Decision aids that present absolute risk estimates and visual risk illustrations enhance the quality of shared decisions. – American College of Endocrinology & American Association of Clinical Endocrinologists 15
Regular follow‑up contact with healthcare professionals after treatment initiation further supports medication adherence. – American College of Endocrinology & American Association of Clinical Endocrinologists 15

Pharmacologic Management of Osteoporosis

First‑Line Pharmacologic Therapy for Women

For women with confirmed osteoporosis, prescribe oral alendronate 70 mg weekly or risedronate 35 mg weekly as the initial therapy to lower hip and vertebral fracture incidence. Strong recommendation (American College of Physicians) 17
In high‑risk women (T‑score ≤ ‑2.5, prior fragility fracture, or FRAX ≥ 20 % 10‑year major osteoporotic fracture risk or hip fracture risk ≥ 3 %), oral alendronate or risedronate remains the preferred first‑line agent. Strong recommendation (American College of Physicians) 17

Alternatives When Oral Bisphosphonates Are Contra‑indicated

Use denosumab 60 mg subcutaneously every 6 months or zoledronic acid 5 mg IV annually for patients unable to take oral bisphosphonates (e.g., esophageal disease, inability to remain upright). Strong recommendation (American College of Physicians) 17

Efficacy of First‑Line Agents

Alendronate, risedronate, zoledronic acid, and denosumab each achieve a 40‑53 % reduction in hip fracture risk. Strong recommendation (American College of Physicians) 17

Treatment of Men with Osteoporosis

Men diagnosed with osteoporosis should receive bisphosphonate therapy to diminish vertebral fracture risk; the supporting evidence is weaker than that for women. Conditional recommendation (American College of Physicians) 17

Non‑Pharmacologic Foundations (Applicable to All Patients)

Ensure daily calcium intake of 1,000–1,200 mg (diet plus supplements as needed). Strong recommendation (American College of Physicians) 17
Provide vitamin D supplementation of 800–1,000 IU per day. Strong recommendation (American College of Physicians) 17

Treatment Duration and Drug Holidays

Initiate a minimum of 5 years of pharmacologic therapy in osteoporotic women. Strong recommendation (American College of Physicians) 17
After 5 years of oral bisphosphonates (or 3 years of zoledronic acid), a drug holiday may be considered only if the patient’s fracture risk is no longer high (T‑score > ‑2.5, fracture‑free, no new risk factors). Conditional recommendation (Endocrine Society) 18
In very high‑risk patients, continue oral bisphosphonates up to 10 years or zoledronic acid up to 6 years. Conditional recommendation (Endocrine Society) 18
Drug holidays are not advised for denosumab; abrupt discontinuation without subsequent bisphosphonate therapy leads to severe rebound vertebral fractures. Strong recommendation (Endocrine Society) 18

Monitoring During Therapy

Do not perform routine BMD (DXA) monitoring during the first 5 years of treatment. Strong recommendation (American College of Physicians) 17
When a drug holiday is contemplated or after 5 years of therapy, repeat DXA at the same facility with the same scanner to evaluate bone stability. Conditional recommendation (Endocrine Society) 18
Reinstitute therapy if a new fracture occurs, BMD declines beyond the least‑significant change, or overall fracture risk rises. Conditional recommendation (Endocrine Society) 18

Denosumab‑Specific Considerations

Upon stopping denosumab, a mandatory transition to a bisphosphonate is required; failure results in rapid bone loss and multiple vertebral fractures within 6–12 months. Strong recommendation (Endocrine Society) 18
Avoid denosumab in immunosuppressed patients due to insufficient safety data. Conditional recommendation (American College of Rheumatology) 19

Glucocorticoid‑Induced Osteoporosis (GIOP) – High‑Risk Patients

First‑line therapy for high‑risk GIOP should be an oral bisphosphonate; if unsuitable, proceed to IV bisphosphonate, then teriparatide, and finally denosumab (used only as a last‑line option). Conditional recommendation (American College of Rheumatology) [19][20]

Medications to Avoid for Osteoporosis Treatment

Menopausal estrogen therapy, combined estrogen‑progestogen therapy, and raloxifene are not recommended for osteoporosis because their cerebrovascular, thromboembolic, and breast‑cancer risks outweigh fracture‑prevention benefits. Strong recommendation (American College of Physicians) 17
Raloxifene may be considered only for postmenopausal women when all other agents are unsuitable. Conditional recommendation (American College of Physicians) 17

Safety Pitfalls and Age‑Specific Concerns

Failing to transition patients off denosumab, romosozumab, or PTH/PTHrP agents to a bisphosphonate markedly increases the risk of severe rebound vertebral fractures. Strong recommendation (Endocrine Society) 18
Prescribing IV bisphosphonates to low‑risk patients younger than 40 years exposes them to unnecessary adverse effects. Conditional recommendation (American College of Rheumatology) 21

Management of Treatment Failure

If a patient experiences a fracture or a BMD decline of ≥10 % per year after ≥18 months of oral bisphosphonate therapy, switch to a different drug class (e.g., teriparatide, denosumab, or IV bisphosphonate if absorption or adherence is problematic). Conditional recommendation (American College of Rheumatology) [19][20]

Osteoporosis Screening, Risk Assessment, and Management Guidelines

Screening and Diagnosis

DXA screening is recommended for all postmenopausal women aged ≥ 65 years and men aged ≥ 70 years at the lumbar spine, total hip, femoral neck, and, when indicated, the one‑third radius.  22
Younger postmenopausal women (50–64 years) and men (50–69 years) should receive DXA only if they have clinical risk factors such as a prior fragility fracture, parental hip fracture, current smoking, excessive alcohol intake (≥ 3 drinks/day), low body weight, chronic glucocorticoid therapy, or secondary‑osteoporosis conditions. [23][22]
Vertebral fracture assessment (VFA) by DXA or conventional spine radiography is indicated in patients ≥ 50 years with a T‑score < –1.0, height loss > 4 cm, self‑reported vertebral fracture, or chronic glucocorticoid use ≥ 5 mg/day prednisone for ≥ 3 months. 24

Fracture Risk Assessment

Apply the FRAX tool to all adults ≥ 40 years to estimate 10‑year probabilities of major osteoporotic fracture and hip fracture; FRAX is not validated for individuals < 40 years. [25][23]
Pharmacologic treatment is indicated when FRAX predicts a 10‑year major osteoporotic fracture risk ≥ 20 % or a hip fracture risk ≥ 3 %. 23
For patients on prednisone > 7.5 mg/day, multiply the FRAX major osteoporotic fracture risk by 1.15 and the hip fracture risk by 1.20 to adjust for glucocorticoid dose. 26
FRAX tends to underestimate risk in patients on very high glucocorticoid doses (≥ 30 mg/day), those with multiple prior fractures, frailty, or recent falls; clinical judgment should supplement FRAX in these scenarios. 25

Risk Stratification (American College of Endocrinology & AACE)

Very high fracture risk is defined by a 3‑year fracture probability ≥ 10 % or any of the following: T‑score ≤ –3.0, fracture within the past 12 months, fractures while on osteoporosis therapy, multiple fractures, ongoing glucocorticoid therapy, high fall risk, or FRAX major osteoporotic fracture > 30 % / hip fracture > 4.5 %. 23
High fracture risk includes T‑score ≤ –2.5, a history of fragility fracture, or FRAX values meeting the treatment thresholds above. 23
Moderate fracture risk corresponds to a 3‑year fracture probability > 3 % but below the very‑high thresholds. 23

Non‑Pharmacologic Management (American College of Endocrinology & AACE)

All patients should obtain 1,000–1,200 mg elemental calcium daily (diet plus supplements) and 800–1,000 IU vitamin D daily; serum 25‑hydroxyvitamin D should be maintained ≥ 30 ng/mL. [27][23]
Weight‑bearing exercise combined with balance training, flexibility/stretching, and progressive resistance strengthening is advised for all patients. 23
Smoking cessation and limiting alcohol intake to ≤ 1–2 drinks per day are recommended. 23
Fall‑prevention programs and referral to physical therapy are recommended for elderly patients with balance impairment or prior falls. 23

Pharmacologic Treatment by Risk Category

Very High Fracture Risk (3‑year risk ≥ 10 %) – American College of Rheumatology (ACR)

Anabolic agents (teriparatide, abaloparatide, or romosozumab) are the preferred first‑line therapies over anti‑resorptives. [25][23]
Romosozumab provides combined anabolic and anti‑resorptive effects. 23
After completing an anabolic course (typically 12–24 months), transition immediately to a bisphosphonate to prevent rebound bone loss and vertebral fractures. [25][27]

High Fracture Risk – ACR & AACE

Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) are first‑line therapy. [25][26]23
If oral bisphosphonates are contraindicated or not tolerated, use denosumab 60 mg subcutaneously every 6 months or intravenous zoledronic acid 5 mg annually. [25][26]23
For adults ≥ 40 years at high risk, denosumab or PTH/PTHrP agents are conditionally preferred over bisphosphonates. 25

Moderate Fracture Risk – ACR

Oral or IV bisphosphonates, denosumab, or PTH/PTHrP agents are all acceptable; choice should consider gastrointestinal tolerability, adherence potential, cost, and patient preference. 25

Treatment Duration and Drug Holidays (AACE)

Initiate a minimum of 5 years of oral bisphosphonate therapy or 3 years of IV zoledronic acid. 27
After 3–5 years of bisphosphonate therapy, reassess fracture risk; continue therapy for patients who remain at high risk, and consider a bisphosphonate “holiday” for those at low‑to‑moderate risk. 27
A bisphosphonate holiday may last up to 5 years; during the holiday, reassess risk every 2–4 years and restart therapy if BMD declines beyond the least significant change, a new fracture occurs, or clinical risk status changes. 27
Drug holidays are not recommended for denosumab; abrupt discontinuation without subsequent bisphosphonate therapy leads to severe rebound vertebral fractures within 6–12 months. 27
When stopping denosumab, romosozumab, or PTH/PTHrP agents, transition immediately to a bisphosphonate to prevent rebound bone loss. [25][27]

Glucocorticoid‑Induced Osteoporosis (GIOP) – ACR

Adults receiving ≥ 2.5 mg/day prednisone (or equivalent) for > 3 months should be screened within 6 months using FRAX (age ≥ 40) plus DXA with VFA or spine radiographs. [25][26]
All adult patients with medium, high, or very high fracture risk should be offered osteoporosis pharmacotherapy. 25
Oral bisphosphonates are strongly recommended as first‑line therapy for high or very high fracture‑risk GIOP. [25][26]
For very high‑risk GIOP, anabolic agents (PTH or PTHrP) are conditionally recommended over anti‑resorptives. 25
Denosumab is a last‑line option in GIOP due to limited safety data in immunosuppressed patients. 25

Special Populations

Women of Childbearing Potential – ACR

Women at moderate‑to‑high fracture risk who do not plan pregnancy during the treatment period and use effective contraception may be treated with oral bisphosphonates. 26
Teriparatide is the preferred alternative if oral bisphosphonates are unsuitable; IV bisphosphonates and denosumab should be reserved for high‑risk patients because of potential fetal risks. 26

Adults < 40 Years – AACE (Z‑score guidance)

Use Z‑scores rather than T‑scores; a Z‑score ≤ –2.0 indicates low bone mass for age. 26
In adults < 40 years with a history of osteoporotic fracture or ongoing glucocorticoid therapy (≥ 7.5 mg/day for ≥ 6 months) who have a hip or spine Z‑score < –3 or bone loss ≥ 10 %/year, consider an oral bisphosphonate. 26

Medication Avoidance – AACE

Menopausal estrogen therapy, combined estrogen‑progestogen therapy, and raloxifene are not recommended for osteoporosis because their cerebrovascular, thromboembolic, and breast‑cancer risks outweigh fracture‑prevention benefits. 26

Treatment Failure and Therapy Switching – ACR

If BMD declines ≥ 10 %/year or fractures recur after ≥ 18 months of oral bisphosphonate therapy, switch to an injectable anti‑resorptive (denosumab or IV zoledronic acid) or an anabolic agent. [25][27]
If a patient is already on an injectable anti‑resorptive and experiences treatment failure, switch to an anabolic agent (abaloparatide, romosozumab, or teriparatide). 25

Common Pitfalls – ACR

Failure to transition patients off denosumab, romosozumab, or PTH/PTHrP agents to a bisphosphonate markedly increases the risk of severe rebound vertebral fractures. [25][27]
FRAX underestimates fracture risk in patients on very high glucocorticoid doses (≥ 30 mg/day prednisone); apply clinical judgment and dose‑adjustment factors. 25
Relying solely on BMD without incorporating clinical risk factors leads to missed high‑risk patients; always use FRAX in conjunction with DXA. 23